Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: A substance for use as a medicament, comprises a solid mixed metal compound of formula (I): MII1-aMIIIaObAn?c.zH2O (I) where MII is at least one bivalent metal: MIII bis at least one trivalent metal; An? is at least one n-valent anion; 2+a=2b+?cn; and ?cn<0.9a. The substance may be made by heating at a temperature of from 200° C. to 600° C., preferably from 250° C. to 500° C. of a substance comprising a compound of formula (II): MII1-xMIIIx(OH)2An?y.mH2O (II) where MII is at least one bivalent metal; MIII is at least one trivalent metal; An? is at least one n-valent anion; x=?yn 0<x?0.5, 0<y?1 and 0<m?10.

Abstract: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: The present invention relates to mixed metal compounds having pharmaceutical activity, especially as phosphate binders. It also extends to methods of manufacture of those compounds, as well as to pharmaceutical compositions containing such compounds. It further relates to their pharmaceutical use. In particular, the present invention relates to use of compounds of Formula (I): MII1-aMIIIa wherein M is at least one bivalent metal (i.e. with two positive charges); M1 is at least one trivalent metal (i.e. with three positive charges); and 1>a>0.4.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: There is provided a granular material comprising (i) at least 50% by weight based on the weight of the granular material of solid water-insoluble mixed metal compound capable of binding phosphate of formula (I): MII1?xMIIIx(OH)2?n?y.ZH2O (I) where MII is at least one of magnesium, calcium, lanthanum and cerium; MIII is at least iron(III); ?n? is at least one n-valent anion; x=?ny; 0<x?0.67, 0<y?1, and 0?z<10; (ii) from 3 to 12% by weight based on the weight of the granular material of non-chemically bound water, and (iii) no greater than 47% by weight based on the weight of the granular material of excipient.

Abstract: A substance for use as a medicament, comprises a solid mixed metal compound of formula (I): MII1?aMIIIaObAn?c.zH2O (I) where MII is at least one bivalent metal: MIII bis at least one trivalent metal; An? is at least one n-valent anion; 2+a=2b+?cn; and ?cn<0.9a. The substance may be made by heating at a temperature of from 200° C. to 600° C. preferably from 250° C. to 500° C. of a substance comprising a compound of formula (II): MII1?xMIIIx(OH)2An?y.mH2O (II) where MII is at least one bivalent metal; MIII is at least one trivalent metal; An? is at least one n-valent anion; x=?yn 0<x?0.5, 0<y?1 and 0<m?10.

Abstract: A method and a kit for conducting marketing research in which respondents evaluate a program and commercials using DVD technology.

Abstract: A delayed and sustained release composition of an additive and/or toxic agent such as nicotine is delivered systemically in therapeutic amounts while avoiding the peak plasma levels which gives rise to addiction and/or toxic side effects. The composition is delivered for absorption predominantly from the colon.

Abstract: A complex of an amide-type anesthetic, such as lignocaine, and a carbomer is effective as a topical composition for the treatment of pain, and in particular for the treatment of inflammatory bowel disease.

Abstract: A method is provided to treat inflammatory bowel disease by locally administering to the colon an effective amount of nicotine or a pharmaceutically acceptable salt thereof, preferably via formulations adapted for delayed oral release or rectal administration. Further provided is a novel formulation for the oral administration of nicotine comprising a polyacrylic polymer complexed with nicotine.